Leveraging Early Structural Insights to Accelerate & De-Risk Bispecific Antibody Lead Design
23 Jun 2025
Bi/Multispecifics
- How can early-stage structural data ensure bispecific antibodies maintain simultaneous target engagement without compromising binding efficacy
- What data can we leverage early to predict and prevent common bispecific developmentability issues such as aggregation and immunogenicity?
- How can detailed structural characterization and epitope maps help close the gap between in vitro promise and in vivo efficacy?
- What types of data are most valuable for understanding complex underlying biology, and how impactful could high-resolution structural and conformational dynamic insights be in addressing these challenges?
- At what stage in your bispecific antibody workflow have structural insights proven most impactful, and why?
- What best practices ensure early structural insights truly accelerate lead optimization?
- How do structural analytics influence your approach to selecting and validating bispecific candidates for clinical advancement?
- What role do epitope-level insights play in streamlining your bispecific lead optimization and reducing downstream risk?
